Cargando…
Biosimilar Tenecteplase Versus Alteplase in Acute Ischemic Stroke: A Real World Study
BACKGROUND AND PURPOSE: There is an unmet need for a more effective thrombolytic agent in acute ischemic stroke (AIS) management. Various studies and meta-analysis suggest tenecteplase (TNK) as non-inferior over alteplase (rTPA). The present single-center study compares biosimilar TNK and rTPA in a...
Autores principales: | Mohan, Ayush, Komakula, Snigdha, Murali, Suhas, Anand, Pooja, Shah, Dyuti, Vishnu, VY, Pandit, Awadh Kishor, Agarwal, Ayush, Vibha, Deepti, Singh, Mamta Bhushan, Padma Srivastava, MV, Bhatia, Rohit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081554/ https://www.ncbi.nlm.nih.gov/pubmed/37034051 http://dx.doi.org/10.4103/aian.aian_754_22 |
Ejemplares similares
-
Replacing Alteplase with Tenecteplase: Is the Time Ripe?
por: Singh, Nishita, et al.
Publicado: (2023) -
Impact of COVID-19 pandemic on incidence of health-care associated infections in neurology intensive care unit (ICU) and its associated mortality – A retrospective cohort study
por: Sudheer, Pachipala, et al.
Publicado: (2021) -
Tenecteplase or Alteplase: What Is the Thrombolytic Agent of the Future?
por: Mahmood, Ammad, et al.
Publicado: (2022) -
Alteplase or tenecteplase for thrombolysis in ischemic stroke: An illustrated review
por: Zhu, Annie, et al.
Publicado: (2022) -
Expanding Footprints of Biosimilar Tenecteplase
por: Subhash, et al.
Publicado: (2023)